Nussbaum Abraham M, Stroup T Scott
Department of Psychiatry, University of North Carolina Hospitals, Chapel Hill, NC 27599-7160, USA.
Schizophr Bull. 2008 May;34(3):419-22. doi: 10.1093/schbul/sbn015. Epub 2008 Mar 28.
In short-term studies, oral paliperidone is an antipsychotic that is more efficacious than placebo. We found its adverse effects to be similar to those of its parent compound, risperidone, with movement disorders, weight gain, and tachycardia all more common with paliperidone than placebo. In addition, paliperidone is associated with substantial increases in serum prolactin that may be associated with sexual dysfunction, although sexual functioning outcomes were not reported. At doses greater than 3 mg per day, oral paliperidone appears comparable in efficacy to oral olanzapine 10 mg per day. Regarding the critical comparison of oral paliperidone to risperidone, we have no information and are thus unable to determine if paliperidone has any advantages or disadvantages compared to its well-known parent compound.
在短期研究中，口服帕利哌酮是一种比安慰剂更有效的抗精神病药物。我们发现其不良反应与母体化合物利培酮相似，帕利哌酮引起的运动障碍、体重增加和心动过速比安慰剂更为常见。此外，帕利哌酮与血清催乳素大幅升高有关，这可能与性功能障碍有关，尽管未报告性功能结果。每日剂量大于3毫克时，口服帕利哌酮的疗效似乎与每日口服10毫克奥氮平相当。关于口服帕利哌酮与利培酮的关键比较，我们没有相关信息，因此无法确定帕利哌酮与其知名母体化合物相比有哪些优势或劣势。
